The Speed of mTOR
At Tumor Oxygen Levels, mTOR Is Loner, Complicating Targeting
By Anette Breindl
Friday, March 29, 2013
By using a single-cell proteomics approach, researchers have discovered that the mammalian target of rapamycin, or mTOR protein, may be hardest to drug at oxygen levels that are often found in tumors. In the most practical sense, the work may help explain why the clinical success of inhibiting mTOR has been mixed.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.